BMS vet joins Kleo Therapeutics as CEO

pharmafile | June 13, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Kleo Pharmaceutical 

Kleo Pharmaceutical has moved to appoint industry veteran Doug Manion to the position of CEO. Kleo are a biotech company that is developing a new class of immunotherapies. It will be hoping to utilise Manion’s experience at BMS to help its therapies through development.

The press release cites Manion’s work on 10 drugs that went onto achieve blockbuster status globally, as well as his work with 20 major brands.

Manion brings with him experience 12 years of experience working at Bristol-Myers Squibb, where his last role saw him perform the role of Senior Vice President, Head of Specialty Development. Prior to this, he had experience working with GSK and DuPont Pharmaceuticals. He will balance the role alongside his non-executive position as Board Member for Celleron Therapeutics.

“I am thrilled to join Kleo Pharmaceuticals as it accelerates its quest to provide novel immunotherapies for patients with high unmet medical need. The science is so compelling. I look forward to partnering with the scientists at Kleo led by David Spiegel and the rest of the team, in advancing a truly innovative approach to enlist patients’ own immune systems to fight serious disease,” said Doug Manion.

Manion will replace Spiegel as the CEO, who will take up the position of President.

“We are delighted to welcome Doug to Kleo. It was clear from day one that Doug shared our passion for bringing innovative immunotherapy solutions to patients in need. His extensive experience and broad connections to the pharmaceutical and investor communities will be invaluable as Kleo Pharmaceuticals evolves into an industry leader,” said David Spiegel.

Related Content

BMS acquires Mirati Therapeutics for $4.8bn

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …

BMS shares new research and development  plans at the company’s R&D day

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …

BMS follow-up data sees long-term survival for melanoma patients

Bristol Myers Squibb (BMS) has announced follow-up data from their Phase III CheckMate-067 clinical trial, …

Latest content